Investors
De-risked path to market
Hardware margin >50% at scale, razor-razorblade model via consumables and software.
Market
QC & analytics TAM $Xbn. Early traction with top-10 pharma.
Moat
Proprietary sensor fusion + validated datasets.
Roadmap
Regulatory milestones and SKU expansion.